Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Learn more about:
Related Clinical Trial
Research on Optimization and Evaluation of Oral Cancer Screening Methods Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings Topical Aldara (Imiquimod) for Oral Cancer Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions LLL Phototherapy in Oral Lesions Resulting From Anti-neoplastic Treatment Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial Understanding Non-radiotherapy-based Development of Trismus Use of Ultrasound for Measuring Size of Oral Tongue Cancers Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients Oral Cancer Screening and Education in Hong Kong Evaluating Oral Visual Inspection in the Control of Oral Cancer Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Effects of EMG Visual Feedback for Spinal Accessory Nerve Dysfunction After Neck Dissection: a Randomized Clinical Trial Prevention of Oral DNA Damage by Black Raspberries Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma NBI in Oral Cavity Cancer Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer Physical Activities by Technology Help (PATH) Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients Patient Evaluation for Head and Neck Surgery Branch Studies Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy Prospective Analysis of Robot-Assisted Surgery Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Cigarette Smoking and Oral Microbiota Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis Least Invasive Nonlinear Light Microscopy Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients Improving Access to Control of Diseases for Women IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Submandibular Gland Preservation in Neck Dissection uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression The Use of Functional Confections in Promoting Oral Health The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis. Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions Wild Type p53 Adenovirus for Oral Premalignancies Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Trial of IIb Preserving Neck Dissection Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Innovative Approach to Triage Oral Precancer The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Rehabilitation Outcomes in Head and Neck Survivors Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions The Relation of Microtubule-Associated Protein 2 and Cell Migration Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study) Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue Oral Pathology Asynchronous Telementoring Pilot Study Polarized Reflectance Spectroscopy for Oral Lesions A Study of the Effects of PEITC on Oral Cells With Mutant p53 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer – COOLS TRIAL Assessment of Mandibular Bone Invasion With MRI Using SWIFT Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients Epstein-Barr Detection in Oral Cancer Workplace Tobacco Cessation And Oral Cancer Screening Study Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity Personalized Survivor Care Plan for Oral Cancer Patients-Effects on Physical-Psychological Functions and Return-to-Work Dental Hygienists and Dentists as Providers of Oral Mucosa Screening and Brush Biopsies Effects of Mouth-opening Training on the Maximum Interincisal Opening Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy – 3-years Prospective Study Erlotinib Prevention of Oral Cancer (EPOC) Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer. Validation of DNA Methylation Biomarkers for Oral Cancer Detection Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions PET/CT and Sentinel Node in Oral Cancer Validation of DNA Methylation Biomarkers for Oral Cancer Detection Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients Using an APP in Post Oral Cancer Surgery to Affect Patients’ Needs and Quality of Life.

Brief Title

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Official Title

A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma

Brief Summary

      This randomized phase I/II trial studies the side effects, best way to give, and best dose of
      erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and
      cetuximab together with or without bevacizumab works in treating patients with metastatic or
      unresectable kidney, colorectal, head and neck, pancreatic, or non-small cell lung cancer.
      Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
      growth. Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
      cells and help kill them or carry tumor-killing substances to them. Cetuximab and bevacizumab
      may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib
      together with cetuximab and/or bevacizumab may kill more tumor cells.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. Determine the maximum tolerated dose (MTD) of erlotinib when combined with cetuximab in
      patients with metastatic or unresectable renal cell, colorectal, head and neck, pancreatic,
      or non-small cell lung cancer (part 1).

      II. Determine the MTD of bevacizumab when combined with cetuximab and erlotinib in these
      patients (part 2).

      III. Determine the toxic effects, both quantitatively and qualitatively, of these regimens in
      these patients.

      IV. Determine the antitumor activity of these regimens, in terms of tumor response,
      short-term survival, and progression-free survival, in these patients.

      SECONDARY OBJECTIVES:

      I. Compare, preliminarily, the toxicity and antitumor activity profiles of these regimens in
      these patients.

      OUTLINE: This is an open-label, multicenter, dose-escalation study of erlotinib and
      bevacizumab.

      Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive
      cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.

      Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose-limiting toxicity.

      Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1.
      Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.

      Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined.
      The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience
      dose-limiting toxicity.

      In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or
      disease progression.

      After completion of study treatment, patients are followed at 1 month.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Maximum tolerated dose (MTD) of erlotinib hydrochloride combined with cetuximab determined by dose-limiting toxicities (DLT) graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3 (Part I)

Secondary Outcome

 Antitumor activity defined as the number and extent (complete or partial) objective responses as well as objective stable disease as measured by RECIST criteria

Condition

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma

Intervention

erlotinib hydrochloride

Study Arms / Comparison Groups

 Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)
Description:  Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.
Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

66

Start Date

January 2005

Completion Date

May 2008

Primary Completion Date

October 2007

Eligibility Criteria

        Inclusion Criteria:

          -  One of the following histologically confirmed diagnoses:

               -  Renal cell cancer

                    -  Clear cell histology

                    -  Metastatic or unresectable disease AND meets 1 of the following criteria:

                         -  Recurrent disease

                         -  Refractory to interleukin-2 (IL-2)- or interferon-based therapy

                         -  Previously untreated AND not a candidate for IL-2-based therapy

               -  Colorectal, head and neck, pancreatic, or non-small cell lung cancer

                    -  Metastatic or unresectable disease

                    -  Progression after prior standard treatment

          -  No evidence of CNS disease, including the following (part 2 only):

               -  Primary brain tumor

               -  Brain metastases

          -  Paraffin embedded tumor blocks available

          -  Performance status - ECOG 0-2

          -  Performance status - Karnofsky 60-100%

          -  More than 12 weeks

          -  Absolute neutrophil count ≥ 1,500 mm^3

          -  Platelet count ≥ 100,000 mm^3

          -  Bilirubin ≤ 1.5 mg/dL

          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastasis
             is present)

          -  PTT and INR ≤ 1.5, unless receiving full-dose warfarin (part 2 only)

          -  Creatinine ≤ 1.5 times ULN

          -  Creatinine clearance ≥ 60 mL/min

          -  Calcium < 10 mg/dL (hypocalcemic agents allowed)

          -  No proteinuria*

          -  Protein < 1 g on 24-hour urine collection*

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No symptomatic congestive heart failure

          -  None of the following are allowed for part 2:

               -  Myocardial infarction within the past 6 months

               -  New York Heart Association class II-IV heart disease

               -  Serious cardiac arrhythmia requiring medication

               -  Peripheral vascular disease ≥ grade II

               -  Recent history of cerebrovascular accident

               -  Uncontrolled hypertension (blood pressure ≥ 150/85 mm Hg despite medication)

               -  Other clinically significant cardiovascular disease

          -  No gastrointestinal (GI) tract disease resulting in an inability to take oral
             medication

          -  No GI tract disease resulting in a requirement for IV alimentation

          -  No active peptic ulcer disease

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biologic composition to study drugs

          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies (part 2 only)

          -  No ongoing or active infection

          -  No active infection requiring parenteral antibiotics (part 2 only)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 2 months after study
             treatment

          -  No significant traumatic injury within the past 28 days (part 2 only)

          -  No history of abnormalities of the cornea (e.g., dry eye syndrome, Sjögren's syndrome,
             or congenital abnormality [e.g., Fuch's dystrophy])

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or
             carcinoma in situ of the breast or cervix

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No serious or non-healing wound ulcer or bone fracture (part 2 only)

          -  No other uncontrolled illness

          -  See Disease Characteristics

          -  More than 4 weeks since prior immunotherapy

          -  No prior cetuximab

          -  No prior bevacizumab

          -  Concurrent epoetin alfa or darbepoetin alfa allowed

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

          -  More than 4 weeks since prior radiotherapy

          -  No prior surgical procedures affecting absorption

          -  Prior nephrectomy or resection of metastatic lesions allowed provided patient has
             fully recovered

          -  More than 7 days since prior core biopsy*

          -  More than 28 days since prior major surgery or open biopsy*

          -  No concurrent major surgery*

          -  Recovered from all prior therapy

          -  No prior erlotinib

          -  Concurrent bisphosphonates allowed

          -  Concurrent full-dose anticoagulants allowed provided the following criteria are met
             (part 2 only):

               -  In-range INR (usually between 2 and 3) AND on a stable dose of warfarin or low
                  molecular weight heparin

               -  No active bleeding

               -  No pathological conditions that carry a high risk of bleeding (e.g., tumor
                  involving major vessels or varices)

          -  No other concurrent investigational agents

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent anticancer therapy
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Alain Mita, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00101348

Organization ID

NCI-2012-02639

Secondary IDs

NCI-2012-02639

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Alain Mita, Principal Investigator, Cancer Therapy and Research Center at The UT Health Science Center at San Antonio


Verification Date

December 2012